IRC unveils comprehensive analysis of the UK's deep biotech infrastructure landscape

Maddie Cass.png

In this blog, Maddie Cass, Senior Policy and Public Affairs Executive at the BIA, shares insights on the Innovation & Research Caucus (IRC) recent report, which examines the current state of the UK's non-health engineering biology infrastructure.


The Innovation & Research Caucus (IRC) has published a report that examines the current state of the UK's non-health engineering biology infrastructure. It offers a detailed analysis of the business, innovation and commercialisation landscape across four key sectors: agri-food, chemicals, materials, and environment. For more information, please refer to the full report.

A key motivator behind this report was to investigate the reasons for the UK's relative lag in commercialisation of non-health engineering biology applications. IRC’s investigation revealed that the UK hosts seven diverse and dynamic clusters of engineering biology activity, but these are hindered by significant gaps in the infrastructure that are impeding commercialisation. For example, half of the regional clusters lacked access to facilities for higher Technology Readiness Levels (TRLs), and agri-food companies were held back by difficulty accessing scale-up fermentation equipment. The findings underscore the vital role of a robust support ecosystem, which is essential for the growth and development of start-up and scaling firms in this sector.

The report's release is particularly timely given the Government’s commitment to engineering biology set out in the National Vision for Engineering Biology and the progress update to the Science and Technology Framework. The Government has committed to invest £2 billion in the sector over the next 10 years. As the Government explores various strategies to establish the necessary infrastructure to support engineering biology in the UK, active involvement from industry stakeholders will be crucial.

The BIA sat on the advisory board of the IRC report and welcomed its publication. We firmly believe in the transformative potential of engineering biology in and beyond health to reconfigure the economy and bring about the biorevolution.

To advance our efforts in the Deep Biotech space, we are expanding our operations and supporting companies leveraging modern biotechnologies to address humanity's most profound challenges, including climate change, pollution and food security.

Learn more about Deep Biotech and our plans to support the burgeoning community in our report - Deep Biotech: Disruptive innovation for global sustainability.

 

More news and updates 

A critical time for AI, dementia and better brain health

Ahead of BioBeat24, Iraida Soria-Espinosa, Senior Innovation & Business Manager at UK DRI, and Miranda Weston-Smith, Founder of BioBeat, caught up with keynote speaker Zoe Kourtzi, Professor of Computational Cognitive Neuroscience at the University of Cambridge.

CEO Update - 7 May 2024

It’s SynBioBeta week and the UK engineering biology community is out in force in San Jose, California. The BIA is leading a coalition of UK stakeholders to showcase the dynamism and innovation of the UK's companies. Read on for updates on local election results, Innovation Map and Deaf Awareness Week...

Paul Freemont's speech on engineering biology at 10 Downing Street reception

Professor Paul Freemont, Faculty of Medicine, Department of Infectious Disease at Imperial College shares insights from his speech at the 10 Downing Street reception. Discover the dynamic landscape of UK engineering biology, where innovation meets sustainability, and explore the vibrant ecosystem of pioneering companies poised to revolutionize industries worldwide.

Deep Biotech companies using engineering biology for good: Evonetix case study

Evonetix is developing a new tool that lets researchers build the building blocks of life – genes – faster and easier than ever before. This could lead to breakthroughs in medicine and agriculture. Read more in BIA's Deep Biotech report on disruptive innovation for global sustainability.

CEO Update - 29 April 2024

Much of the UK will go to the polls this Thursday in the biggest test of public opinion ahead of the UK general election. Ten key metro mayoral contests take place including in Tees Valley, Manchester, the West and East Midlands and London. The results will be announced over the weekend and give a new mandate to key figures in regions of the UK whilst also helping define if we will have a summer or autumn general election.

Harnessing the power of innovation: How the Innovation Map can help your life science company thrive

In this blog, Sam Cruickshank, Programme Manager at BIA, discusses the pivotal role of the recently updated 2024 BIA Innovation Map in empowering life science entrepreneurs to navigate the complexities of the start-up landscape and unlock their ventures' full potential.

RNID shine a spotlight on the hearing therapeutics landscape

In this blog, Melissa Hayman, Hearing Therapeutics Manager at RNID, BIA’s charity partner of the year introduces a blog series to be published over the coming months which will examine the hearing therapeutics landscape.

Continuity and change: Labour’s life science strategy

​​​​Herbie Lambden, Senior Policy and Public Affairs Executive at the BIA, provides a rundown of the BIA Committee Summit, which took place in Westminster on 21 February.

CEO Update - 22 April 2024

The UK's engineering biology scene was out in force at a Number 10 Downing Street reception last week. It was great to celebrate the developments in our community network together with ministers and investors.

Step up and create more inclusive workplaces within the biotech sector

In last year’s Diversity and Inclusion in UK Biotech survey conducted by the BIA, hearing loss emerged as one of the most prevalent disabilities. With Deaf Awareness Week 2024 (6-12 May) fast approaching, the BIA has teamed up with its charity partner, RNID, to offer valuable resources and initiatives for creating more inclusive workplaces across the biotech sector.

 

More within